[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510256":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":35,"responsibleParty":69,"collaborators":25,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":25,"enrollmentInfo":80,"targetDuration":25,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":25,"overallStatus":61,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SF3B1 mutant Myelodysplastic syndromes patients (MDS)","EXPERIMENTAL","Patients diagnosed with MDS carrying the SF3B1 somatic mutation associated myelodysplastic neoplasm with ring sideroblasts",[13],"Biological: Biological sampling",{"label":15,"type":16,"description":17,"interventionNames":18},"Monoclonal Gammapathy of Unknown Significance patients (MGUS)","ACTIVE_COMPARATOR","MGUS patients, referred to as normal bone marrow controls",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Biological sampling","The procedure will consist of an additional bone marrow sample and blood sample",[15,9],null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Victor-Emmanuel BRETT","CONTACT","0556774357","victor.brett@chu-bordeaux.fr",{"name":33,"role":29,"phone":25,"phoneExt":25,"email":34},"Charles DUSSIAU","charles.dussiau@chu-bordeaux.fr",[36,50,59],{"facility":37,"status":38,"city":39,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"CHU de Bordeaux, Laboratoire d'Hématologie","NOT_YET_RECRUITING","Pessac","France","FR",{"type":43,"coordinates":44},"Point",[45,46],-0.6324,44.80565,{"lat":46,"lon":45},[49],{"name":28,"role":29,"phone":25,"phoneExt":25,"email":31},{"facility":51,"status":38,"city":39,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"CHU de Bordeaux, Service de Médecine Interne",{"type":43,"coordinates":53},[45,46],{"lat":46,"lon":45},[56],{"name":57,"role":29,"phone":25,"phoneExt":25,"email":58},"Estibaliz LAZARO","estibaliz.lazaro@chu-bordeaux.fr",{"facility":60,"status":61,"city":39,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire","RECRUITING",{"type":43,"coordinates":63},[45,46],{"lat":46,"lon":45},[66],{"name":67,"role":29,"phone":25,"phoneExt":25,"email":68},"Sophie DIMICOLI-SALAZAR","sophie.dimicoli-salazar@chu-bordeaux.fr",{"type":70,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100510256","ferroptosis-study-in-sf3b1-mutant-myelodysplastic-syndromes-fermds-100510256",false,"NCT05924074","Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)","FerMDS","Inclusion Criteria:\n\nFor all :\n\n* Patients of legal age (age ≥ 18 years)\n* Subjects affiliated to or benefiting from a social security scheme\n* Free, written and informed consent signed by the participant and the investigator\n\nFor MDS patients :\n\n* Sampling at diagnosis for MDS patients (WHO 2016 criteria)\n* Presence of ring sideroblasts on bone marrow smear\n\nFor MGUS patients :\n\n\\- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).\n\nExclusion Criteria:\n\nFor all\n\n* Patient transfused with red blood cells within 120 days prior to collection\n* Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection\n* Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda\n* Person under a legal protection measure (legal protection, guardianship or curatorship)\n* Person deprived of liberty by judicial or administrative decision\n* Person who is unable to give consent\n* Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol","ALL","18 Years",{"count":81,"type":82},80,"ESTIMATED","INTERVENTIONAL",[85],"NA","Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.",[88,89],"Myelodysplastic Syndromes","Ferroptosis","2025-03-18",{"date":92,"type":93},"2025-03-19","ACTUAL",{"date":95,"type":93},"2025-02-21",{"date":97,"type":82},"2027-02",{"name":5,"class":6},3]